Neurocrine Biosciences Names Dr. Gano as President and CEO
Company Announcements

Neurocrine Biosciences Names Dr. Gano as President and CEO

Neurocrine ( (NBIX) ) has shared an update.

Neurocrine Biosciences has appointed Dr. Kyle Gano as their new President and CEO starting October 11, 2024, with a generous compensation package including a $900,000 annual salary, potential 100% bonus, and varied equity grants totaling approximately $1.5 million, which vest over four years. Dr. Gano’s contract also outlines substantial severance benefits in the event of involuntary termination, with specifics dependent on the timing and context of his departure, including potential accelerated equity award vesting and health plan coverage.

Learn more about NBIX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyNeurocrine presents data from Ingrezza studies on tardive dyskines patients
TheFlyNeurocrine presents data from long-term KINECT-4 study
TipRanks Auto-Generated NewsdeskNeurocrine Biosciences’ $300M Share Buyback Plan: Potential Risks and Market Volatility Concerns
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App